research use only
Cat.No.S4058
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR |
|---|---|
| Other Sodium Channel Inhibitors | Camostat Mesilate A-803467 cariporide Veratramine Tolperisone HCl Bulleyaconi cine A Vinpocetine Tenapanor PF-06869206 Sparteine |
|
In vitro |
DMSO
: 62 mg/mL
(199.44 mM)
Ethanol : 62 mg/mL Water : 46 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 310.86 | Formula | C17H26N2O.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 98717-15-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | LEA-103 HCl | Smiles | CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl | ||
| In vitro |
Ropivacaine HCl is a local anaesthetic agent. It elicits nerve block via reversible inhibition of sodium ion influx in nerve fibres. The pKa of this compound is ~8.2. It has the potential to induce cardiovascular toxicity and CNS toxicity at high plasma concentrations.
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04003506 | Not yet recruiting | Pain Postoperative |
The University of Hong Kong |
March 1 2024 | Phase 4 |
| NCT06006026 | Recruiting | Colorectal Cancer |
West China Hospital |
August 28 2023 | Not Applicable |
| NCT05773846 | Recruiting | Bunion |
PainReform LTD|Lotus Clinical Research LLC |
March 13 2023 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.